Novo Nordisk Expands Obesity Pipeline With New First‑in‑Human Trial for NNC0113-5840
Novo Nordisk (NVO) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Novo Nordisk (NVO) has launched a first‑in‑human trial titled “A First in Human Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC0113-5840 in Participants With Overweight or Obesity.” The study aims to see if the new drug is safe and how it behaves in the body, marking an early but important step in Novo’s obesity pipeline.
The trial tests NNC0113-5840, an injectable drug given under the skin in the abdominal area. It is designed to treat people with overweight or obesity, with doses rising step by step to find a safe range, and compared against a placebo that contains no active medicine.
This is a Phase 1 interventional study with people randomly assigned to receive either NNC0113-5840 or placebo. The study is double blind, so neither patients nor investigators know who gets the active drug, and the main goal is to assess safety and basic treatment effects.
The study was first submitted on 2026-04-29, signaling the formal start of the development path for this asset. The most recent update on 2026-06-01 shows the trial is still recruiting, with key readouts such as primary completion and final completion yet to be reported.
For investors, this update reinforces Novo Nordisk’s push to extend its lead in obesity beyond current blockbusters like Wegovy. Positive early safety data could support long‑term growth expectations and keep investor sentiment strong versus rivals such as Eli Lilly, though near‑term stock moves are likely modest until later‑stage data emerge.
The study remains ongoing and updated on the ClinicalTrials portal, where investors can track future milestones and detailed protocol changes.
To learn more about NVO’s potential, visit the Novo Nordisk drug pipeline page.
